Clinical Trials Logo

Clinical Trial Summary

The main objective of this project is not only a better understanding of the human leukemic disease but also to find new anti-leukemic or improve existing ones. This study has, the following aims:

- To analyze the genetic and epigenetic regulation of the retinoic acid induced cascade which leads to the expression of TRAIL in blood cells of patients with acute leukemia. This study will be complemented by the analysis of global gene expression (DNA chips) and of the DNA methylation state, and by chromatin immunoprecipitation experiences.

- To determine the efficiency of inhibitors of enzymes responsible for the modification of chromatin (existing and new developments within the European consortium EPITRON coordinated by Dr Gronemeyer) as inducers of differentiation and / or apoptosis of leukemic blasts.

- To explore Ikaros genic and functional abnormalities (genomic deletions, mutations, abnormal transcripts and proteins) in acute leukemia. The aim is to determine if these abnormalities may play a prognosis role.


Clinical Trial Description

n/a


Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science


Related Conditions & MeSH terms


NCT number NCT00993538
Study type Interventional
Source University Hospital, Strasbourg, France
Contact Raoul Herbrecht, MD
Phone 3.33.88.12.83.79
Email Raoul.herbrecht@chru-strasbourg.fr
Status Recruiting
Phase N/A
Start date July 2009

See also
  Status Clinical Trial Phase
Completed NCT01890746 - A Safety and Efficacy Study of Eltrombopag in Subjects With AML Phase 2
Completed NCT02058888 - Amplification and Selection of Antimicrobial Resistance in the Intestine N/A
Completed NCT01521611 - Targeted Radiotherapy in HSCT for Poor Risk Haematological Malignancy Phase 1/Phase 2
Withdrawn NCT00570999 - Palifermin After Haploidentical PBSCT Phase 2
Recruiting NCT02123836 - Natural Killer Cells in Acute Leukaemia and Myelodysplastic Syndrome Phase 1
Completed NCT00795132 - Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies Phase 2